ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 49,600 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 49,600 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $11.21, for a total value of $556,016.00. Following the completion of the transaction, the director now owns 210,346 shares of the company’s stock, valued at $2,357,978.66. This represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Laura Shawver also recently made the following trade(s):

• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $12.31, for a total value of $615,500.00.
• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.10, for a total value of $555,000.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY traded up $0.06 during trading on Friday, reaching $10.85. 1,415,282 shares of the stock were exchanged, compared to its average volume of 1,340,513. The stock has a fifty day moving average of $11.87 and a two-hundred day moving average of $13.16. ARS Pharmaceuticals, Inc. has a 1-year low of $7.55 and a 1-year high of $18.51. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -21.27 and a beta of 1.03.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SPRY. Bernard Wealth Management Corp. bought a new stake in ARS Pharmaceuticals during the 4th quarter worth approximately $27,000. Ball & Co Wealth Management Inc. purchased a new position in shares of ARS Pharmaceuticals during the fourth quarter valued at approximately $105,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in ARS Pharmaceuticals by 5.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 247,314 shares of the company’s stock worth $2,609,000 after buying an additional 12,777 shares in the last quarter. Woodline Partners LP raised its position in ARS Pharmaceuticals by 13.5% in the 4th quarter. Woodline Partners LP now owns 1,119,283 shares of the company’s stock valued at $11,808,000 after buying an additional 133,276 shares during the last quarter. Finally, Wexford Capital LP lifted its stake in ARS Pharmaceuticals by 48.8% during the 4th quarter. Wexford Capital LP now owns 369,497 shares of the company’s stock valued at $3,898,000 after acquiring an additional 121,150 shares in the last quarter. 68.16% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SPRY has been the subject of several analyst reports. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday. They set a “sector outperform” rating and a $30.00 price target for the company. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday. Raymond James upped their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Oppenheimer assumed coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Leerink Partners upped their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $29.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.